Simultaneous disruption of both BCL-2 and MCL-1 via small-molecule inhibitors induces robust regression of tumors in a SS PDX model and cell-line xenograft model as well as multiple cell lines derived from both primary and metastatic disease. The gene discussed is BCL2; the disease is metastatic neoplasm.